Surrozen (SRZN) Total Non-Current Liabilities (2020 - 2026)
Surrozen (SRZN) posted quarterly Total Non-Current Liabilities of $163.3 million for Q1 2026, up 144.77% year-over-year from $66.7 million in Q1 2025, and up 27.78% quarter-over-quarter from $127.8 million in Q4 2025.
Analysis
Surrozen (SRZN) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Surrozen's Total Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $163.3 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 144.77% year-over-year to $163.3 million; the TTM figure through Mar 2026 stood at $163.3 million (up 144.77% YoY), while the FY2025 annual figure was $127.8 million, up 815.99% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $163.3 million, up from $127.8 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $163.3 million in Q1 2026, with the low at $6.0 million in Q2 2024.
- The 5-year median for Total Non-Current Liabilities is $13.0 million (2022), against an average of $33.2 million.
- The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities sank 39.44% in 2024, then jumped 946.03% in 2025.
- Surrozen's Total Non-Current Liabilities stood at $13.1 million in 2022, then slumped by 38.74% to $8.0 million in 2023, then jumped by 73.79% to $14.0 million in 2024, then surged by 815.99% to $127.8 million in 2025, then grew by 27.78% to $163.3 million in 2026.
- Business Quant data shows SRZN's Total Non-Current Liabilities at $163.3 million in Q1 2026, $127.8 million in Q4 2025, and $64.0 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 3.92 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 1.53 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.88 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 9.32 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Surrozen | 263.35 Mn | 263.35 Mn | - | 138.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 138.00 Mn |
| Mar 31, 2026 | 163.34 Mn |
| Dec 31, 2025 | 127.83 Mn |
| Sep 30, 2025 | 64.02 Mn |
| Jun 30, 2025 | 22.96 Mn |
| Mar 31, 2025 | 59.78 Mn |
| Dec 31, 2024 | 13.96 Mn |
| Sep 30, 2024 | 6.12 Mn |
| Jun 30, 2024 | 5.98 Mn |
| Mar 31, 2024 | 6.40 Mn |
| Dec 31, 2023 | 8.03 Mn |
| Sep 30, 2023 | 8.20 Mn |
| Jun 30, 2023 | 8.62 Mn |
| Mar 31, 2023 | 10.57 Mn |
| Dec 31, 2022 | 13.11 Mn |
| Sep 30, 2022 | 12.61 Mn |
| Jun 30, 2022 | 13.05 Mn |
| Mar 31, 2022 | 13.19 Mn |
| Dec 31, 2021 | 19.17 Mn |
| Sep 30, 2021 | 18.60 Mn |